Core Viewpoint - Zhaoli Pharmaceutical plans to issue convertible bonds to raise up to 1.556 billion yuan for the development of an intelligent traditional Chinese medicine health factory and product research, while also supplementing working capital [1] Group 1: Fundraising and Investment Projects - The company intends to allocate 1.08 billion yuan for the intelligent traditional Chinese medicine health factory, 216 million yuan for the "Wuling + X" product research project, and 250 million yuan for working capital [1] - Prior to the funds being raised, the company will use self-raised funds based on project progress and will replace them with raised funds once available [1] - The board may adjust the order and amount of funds allocated to the projects based on actual needs without changing the nature of the fundraising projects [1] Group 2: Financial Performance and Shareholder Returns - The company has experienced rapid growth in recent years, with a return on invested capital (ROIC) performance that is commendable, although shareholder earnings remain negative due to large capital investments [1] - The company has maintained a stable financial position with a debt ratio around 30%, indicating good debt repayment capability [2] - The company has consistently paid substantial dividends, with a total cash dividend of 942 million yuan from 2022 to 2024, accounting for over 80% of the net profit attributable to shareholders during that period [2] Group 3: Revenue and Profit Growth - The company has shown stable growth in revenue and net profit, with a reported revenue of 2.28 billion yuan for the first three quarters of 2025, representing an 11.48% year-on-year increase, and a net profit of 510 million yuan, up 21.0% year-on-year [4]

Core Viewpoint - Zhaoli Pharmaceutical plans to issue convertible bonds to raise up to 1.556 billion yuan for the construction of an intelligent traditional Chinese medicine health factory, the "Wuling+X" product development project, and to supplement working capital, supporting the company's core business upgrade and innovation [1][2]. Fundraising Purpose - The funds will primarily be allocated to the construction of an intelligent traditional Chinese medicine health factory, which will include GMP-compliant facilities and production lines for medicinal fungi fermentation and extraction, addressing future capacity needs for Wuling capsules and improving competitiveness in the pharmaceutical manufacturing industry [1][2]. - The "Wuling+X" product development project aims to expand the product pipeline with innovative drugs targeting gastrointestinal, urology, and other high-demand clinical areas, leveraging the established market foundation of the Wuling series products [2]. Financial Performance - In Q3 2025, Zhaoli Pharmaceutical reported revenue of 2.28 billion yuan, a year-on-year increase of 11.48%, and a net profit of 510 million yuan, with both metrics reaching historical highs for the same period [2]. - The company plans to use part of the raised funds to optimize its financial structure and alleviate daily operational funding pressures, ensuring support for market expansion as it continues to invest in OTC market layout and multi-channel development [2]. Strategic Focus - Zhaoli Pharmaceutical has adopted a "one body, two wings" strategy, focusing on core business areas and forming three main business segments: finished medicines, decoction pieces, and formula granules [3]. - The company aims to build brand recognition in the consumer market and develop a product matrix covering various health scenarios, establishing the "Wuling+" health brand as a second growth curve [3].

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) plans to participate in a land auction in Deqing County, with a total land area of 126,719 square meters and a budget of up to 65 million yuan for the land use rights [1] Group 1 - The land is located on the south side of Datong Road and the west side of Guandi Road, with the plot number being Fuxi Street G2024-041-2 [1] - The company will use its own funds not exceeding 65 million yuan to participate in the auction for land use rights [1] - The management team has been authorized to handle the auction process and subsequent land purchase procedures, including signing all related documents [1]

格隆汇12月2日丨佐力药业(300181.SZ)公布，拟向不特定对象发行可转换公司债券募集资金总额不超过 155,612.03万元，扣除发行费用后的募集资金净额用于智能化中药大健康工厂（一期）、"乌灵+X"产品 研发项目、补充流动资金。 ...

每经AI快讯，佐力药业12月2日晚间发布公告称，公司第八届第十次董事会临时会议于2025年12月2日 在公司会议室以现场结合通讯方式召开。会议审议了《关于公司未来三年股东回报规划的议案》等文 件。 （记者 张明双） 每经头条（nbdtoutiao）——股民发帖求主力拉涨停，次日竟成真！襄阳轴承涨停迷局背后：平台审核 漏洞与市场操纵疑云发酵 ...

智通财经APP讯，佐力药业(300181.SZ)发布向不特定对象发行可转换公司债券预案，本次向不特定对象 发行可转换公司债券募集资金总额不超过15.56亿元(含本数)，扣除发行费用后的募集资金净额拟用于以 下项目：智能化中药大健康工厂(一期)、"乌灵+X"产品研发项目以及补充流动资金。 ...

佐力药业（300181）(300181.SZ)发布向不特定对象发行可转换公司债券预案，本次向不特定对象发行 可转换公司债券募集资金总额不超过15.56亿元(含本数)，扣除发行费用后的募集资金净额拟用于以下项 目：智能化中药大健康工厂(一期)、"乌灵+X"产品研发项目以及补充流动资金。 ...

证券代码：300181 证券简称：佐力药业 浙江佐力药业股份有限公司 向不特定对象发行可转换公司债券 方案的论证分析报告 银行贷款等债务融资方式相对单一，且融资额度相对有限。若本次募投项目的资金 全部通过银行贷款取得，一方面将导致公司资产负债率提高，加大财务风险；另一方面 较高的财务费用将影响公司利润，降低公司资金使用的灵活性，不利于公司持续经营。 本次发行的可转债在符合条件时可转换为公司股票，相当于在发行公司债券的基础上附 加了一份期权，因此兼具股性和债性。可转换公司债券通常具有较低的票面利率，能够 显著降低公司融资成本。 本次向不特定对象发行可转换公司债券募集资金投资项目均经过公司谨慎论证， 项目的实施有利于进一步提升公司的核心竞争力，增强公司的可持续发展能力，具体 分析详见《浙江佐力药业股份有限公司向不特定对象发行可转换公司债券募集资金使 用可行性分析报告》。 三、本次发行对象的选择范围、数量和标准的适当性 1 本次发行证券的种类为可转换为公司股票的可转换公司债券（以下简称"可转 债"）。本次可转债及未来经本次可转债转换的公司股票将在深圳证券交易所创业板上 市。 二、本次发行选择可转换公司债券的必要性 ...

证券代码：300181 证券简称：佐力药业 公告编号：2025-061 浙江佐力药业股份有限公司 关于向不特定对象发行可转换公司债券预案披露的 提示性公告 浙江佐力药业股份有限公司 董 事 会 2025 年 12 月 2 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于2025年12月2日召开第八 届董事会第十次（临时）会议，审议通过了向不特定对象发行可转换公司债券的 相关议案。《浙江佐力药业股份有限公司向不特定对象发行可转换公司债券预案》 及 相 关 文 件 已 在 中 国 证 监 会 指 定 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露，敬请广大投资者注意查阅。 公司向不特定对象发行可转换公司债券预案披露事项不代表审核、注册部门 对于本次向不特定对象发行可转换公司债券相关事项的实质性判断、确认、批准 或注册。该预案所述本次向不特定对象发行可转换公司债券相关事项的生效和完 成尚需公司股东会审议通过、深圳证券交易所审核通过并经中国证券监督管理委 员会同意注 ...

浙江佐力药业股份有限公司 向不特定对象发行可转换公司债券预案 （浙江省德清县阜溪街道志远北路 388 号） 二〇二五年十二月 证券代码：300181 证券简称：佐力药业 浙江佐力药业股份有限公司 向不特定对象发行可转换公司债券预案 声 明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并对本预案内 容的真实性、准确性、完整性承担个别和连带的法律责任。 2、本次向不特定对象发行可转换公司债券完成后，公司经营与收益的变化 由公司自行负责；因本次向不特定对象发行可转换公司债券引致的投资风险由投 资者自行负责。 3、本预案是公司董事会对本次向不特定对象发行可转换公司债券的说明， 任何与之相反的声明均属不实陈述。 4、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 5、公司向不特定对象发行可转换公司债券预案披露事项不代表审核、注册 部门对于本次向不特定对象发行可转换公司债券相关事项的实质性判断、确认、 批准或注册。该预案所述本次向不特定对象发行可转换公司债券相关事项的生效 和完成尚需公司股东会审议通过、深圳证 ...